The NTG brought together a national panel of expert researchers and practitioners in the field of Down syndrome and Alzheimer’s disease, including LuMind IDSC’s Scientific Chief Officer, Dr. James Hendrix, who discussed the current and future therapeutics, matters related to diagnostics, and the emerging research on biomarkers. This webinar will be useful to parents and families, providers, advocates, clinicians, practitioners, and others invested in the future for persons with Down syndrome.
Source: National Task Group on Intellectual Disabilities and Dementia Practices